Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5069 in uncontrolled persistent asthma (NIMBUS)
NCT01704495Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of azd5069 in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Rate of Severe Asthma Exacerbations During 6 Months. Started Nov 2012; status: completed.
02
Drugs
azd5069
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01704495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704495.